The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg

被引：0

作者：

Bocci, A. ^{[1
]}

Spielniann, D. ^{[1
]}

Azzini, Pr ^{[1
]}

Guaschino, Pr ^{[1
]}

Affronti, G. ^{[1
]}

Villani, Pr ^{[1
]}

Boselli, Pr ^{[1
]}

Genazzani, Pr ^{[1
]}

Flamigni, Z. C. ^{[1
]}

Omodei, U. ^{[1
]}

Bolis, P. ^{[1
]}

Marsoni, V. ^{[1
]}

Luerti, M. ^{[1
]}

Simenel, J. L. ^{[1
]}

Ouvry-Neveu, B. ^{[1
]}

Andre, G. ^{[1
]}

David, S. ^{[1
]}

Durand, J. L. ^{[1
]}

Ehret-Mentre, C. ^{[1
]}

Gensburger, J. M. ^{[1
]}

Goetzmann, P. ^{[1
]}

Jung-Faerber, S. ^{[1
]}

Keller, D. ^{[1
]}

Lempereur, M. ^{[1
]}

Plumere, C. ^{[1
]}

Spielmann, A. ^{[1
]}

Katz, J. L. ^{[1
]}

Sebaoun, J. ^{[1
]}

Belaisch, J. ^{[1
]}

Hammer, F. ^{[1
]}

Salama, B. ^{[1
]}

Aissaoui, S. ^{[1
]}

Taube, A. M. ^{[1
]}

Nakache, H. ^{[1
]}

Soria, J. ^{[1
]}

Joffo, M. ^{[1
]}

Lardenois, H. ^{[1
]}

Leclerc, P. ^{[1
]}

Ponsar, C. ^{[1
]}

Saubry-Bobet, V. ^{[1
]}

Blaiset, E. ^{[1
]}

Veyres, F. ^{[1
]}

Clamp, M. ^{[1
]}

Menon, K. V. K. ^{[1
]}

Moran, D. G. ^{[1
]}

Randall, S. ^{[1
]}

Shaw, P. J. ^{[1
]}

Bruni, V. ^{[1
]}

Massobrio, M. ^{[1
]}

Crosignani, P. ^{[1
]}

机构：

[1] Wyeth Ayersr Res, F-92031 Paris, France

来源：

EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE | 1999年 / 4卷

关键词：

Oral contraceptive; Contraceptive efficacy; Gestodene; Ethinylestradiol;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective The safety and contraceptive efficacy of a new 24-day regimen of an oral contraceptive combination containing gestodene (GTD) 60 mu g and ethinylestradiol (EE) 15 mu g was evaluated in an open-label, multicenter study. Methods Adult women received GTD 60 mu g/EE 15 mu g from day 1 to 24 and 4 days of placebo during a 28-day cycle for either 13 or 19 cycles. Results Of the 1515 subjects enrolled, 1496 were included in the intent-to-treat analysis. A total of three pregnancies were reported during the 18 194 treatment cycles of the study, yielding a Pearl index of 0.21. Life-table analysis, based on 16 954 cycles, gave an accidental pregnancy rate of 0.0033. The most frequent adverse events were headache (reported in 35% of subjects), absence of bleeding (16%), flu-like syndrome (15%), pharyngitis (15%) and abdominal pain (15%). The most frequent reasons for withdrawal from the study were metrorrhagia, flu syndrome and absence of bleeding. Analyses of withdrawal and intermenstrual bleeding and spotting indicated acceptable cycle control. Conclusions The 24-day GTD 60 mu g/EE 15 mu g, regimen appears to be a well-tolerated and effective method for low-dose oral contraception. The current formulation offers an ultra-low steroidal dosage combined with a reduced pill-free interval to improve contraceptive efficacy.

引用

页码：9 / 15

页数：7

共 50 条

[21] Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol
Anderson, FD
Gibbons, W
Portman, D
CONTRACEPTION, 2006, 73 (03) : 229 - 234
[22] A three year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene
Dusterberg, B
Ellman, H
Muller, U
Rowe, E
Muhe, B
GYNECOLOGICAL ENDOCRINOLOGY, 1996, 10 (01) : 33 - 39
[23] A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mu g ethinylestradiol 75 mu g gestodene and 30 mu g ethinylestradiol 75 mu g gestodene, with respect to efficacy, cycle control, and tolerance
Endrikat, J
Muller, U
Dusterberg, B
CONTRACEPTION, 1997, 55 (03) : 131 - 137
[24] Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 mu g ethinylestradiol 75 mu g gestodene and 30 mu g ethinylestradiol 75 mu g gestodene, on lipid metabolism in an open randomized trial
Brill, K
Then, A
Beisiegel, U
Jene, A
Wunsch, C
Leidenberger, F
CONTRACEPTION, 1996, 54 (05) : 291 - 297
[25] Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen
Mansour, Diana
Verhoeven, Carole
Sommer, Werner
Weisberg, Edith
Taneepanichskul, Surasak
Melis, Gian Benedetto
Sundstrom-Poromaa, Inger
Korver, Tjeerd
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2011, 16 (06): : 430 - 443
[26] Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estradiol and 150 μg desogestrel
Endrikat, J
Cronin, M
Gerlinger, C
Ruebig, A
Schmidt, W
Düsterberg, B
CONTRACEPTION, 2001, 64 (03) : 201 - 207
[27] Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits
Heskamp, Marie-Luise S.
Schramm, Georg A. K.
CONTRACEPTION, 2010, 81 (01) : 49 - 56
[28] A comparative clinical investigation of endocrine parameters with two low-dose oral contraceptives containing either 75 μg gestodene or 150 μg desogestrel combined with 20 μg ethinylestradiol
Van Huesden, AM
Fauser, BCJM
Spielman, D
GYNECOLOGICAL ENDOCRINOLOGY, 1998, 12 : 13 - 19
[29] A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism
Endrikat, J
Klipping, C
Gerlinger, C
Ruebig, A
Schmidt, W
Holler, T
Düsterberg, B
CONTRACEPTION, 2001, 64 (04) : 235 - 241
[30] Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy
Wiegratz, Inka
Stahlberg, Skadi
Manthey, Torsten
Saenger, Nicole
Mittmann, Katrin
Lange, Evelyn
Mellinger, Uwe
Palombo-Kinne, Ernesta
Kuhl, Herbert
CONTRACEPTION, 2011, 84 (02) : 133 - 143

← 1 2 3 4 5 →